How it All Plays Out - Research on Amarantus, Global Equity International, Max Sound, and PositiveID
NEW YORK, NY / ACCESSWIRE / October 28, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Amarantus Bioscience Holdings Inc. (OTC: AMBS), Global Equity International Inc. (OTC: GEQU), Max Sound Corp. (OTC: MAXD), and PositiveID Corporation (OTC: PSID). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
To access our full PDF reports for free, please visit the links below.
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
AMBS Research Report: http://www.traders-choice.com/pdf?s=AMBS
GEQU Research Report: http://www.traders-choice.com/pdf?s=GEQU
MAXD Research Report: http://www.traders-choice.com/pdf?s=MAXD
PSID Research Report: http://www.traders-choice.com/pdf?s=PSID
Highlights from today's reports include:
On Tuesday, October 27, 2015, the U.S. markets finished weaker as NASDAQ ended at 5,030.15, down 0.09%, Dow Jones declined 0.24% to finish the day at 17,581.43, and the S&P closed at 2,065.89, down 0.26%.
- Amarantus Bioscience Holdings Inc.'s stock edged higher by 13.18% to close Thursday's session at USD 0.85 as the broader markets ended in the green. The company's shares oscillated between USD 0.77 and USD 0.90 in trade during the day. The biopharma company's stock recorded a trading volume of 0.19 million shares, which was above its 30-day daily average volume of 0.10 million shares. On October 22, 2015, Amarantus Bioscience Holdings, Inc. announced that it has submitted an application to the US FDA, requesting orphan drug designation (ODD) status for eltoprazine. Amarantus Bioscience reported that Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), adult attention deficit hyperactivity disorder (ADHD) and Alzheimer's aggression. According to the Company, Eltoprazine has been evaluated in over 680 human subjects to date, and it has a well-established safety profile. Gerald E. Commissiong, the President and CEO of Amarantus said, "A successful application to the US FDA for ODD for eltoprazine in PD LID would complete the transition of our therapeutics portfolio into the orphan drug arena, thereby squarely positioning Amarantus as an orphan drug company." The release indicated that if approved, FDA Orphan Drug Designation would grant a special status to Eltoprazine with a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.
- The stock of Global Equity International Inc. was up 2.70% in trade to close at USD 0.038 on Thursday. A total of 2.21 million shares were traded during the session, lower than its 30-day average volume of 6.72 million shares. On October 14, 2015, Global Equity International, Inc. announced that it has entered into a strategic partnership agreement with the "Middle East Prospect Exhibition" ("MEPEX"), to act as their exclusive selected Financial Partner for capital raising, Advisory and Public Listings for all of the MEPEX participants. MEPEX attempts at bringing together Companies in the Energy Sector in the Region and providing a market place for buying, selling and financing of Oil and Gas related projects and companies. For its first exhibition, MEPEX has 280 Oil and Gas related participants. Mr. Peter Smith, CEO of Global Equity said, "MEPEX and GEP can together become a significant force in the financing and listing of Oil and Gas companies in the Middle East; with their contact and relationship base and our experience we have a tremendous opportunity in a multi-billion dollar industry. We will finalize the structure of the partnership in the Kingdom of Bahrain in the coming weeks with a view to establishing an 'offering' for the Hydrocarbon community in the Region with MEPEX being the funnel for our consultancy services." Meanwhile, Mr. Habib Al-Alawi, Director of MEPEX, said, "With this strategic partnership we can take MEPEX to the next level as we can now offer a 'complete solution' from showcasing to funding these Exploration & Production opportunities and ultimately listing them on a recognized Stock Exchange."
- Max Sound Corp's stock continued its upward momentum as it soared 24.05% to close Wednesday's session at USD 0.05. The company's shares fluctuated in the range of USD 0.04 and USD 0.05. The stock's trading volume of 6.16 million shares was much above its one month average volume of 2.97 million shares. Earlier on September 17, 2015, Max Sound informed that it has paid filing fees to the German Court to continue their pursuit for justice against Google and its subsidiaries. As per the release, the District Court of Mannheim has scheduled the final hearing in the video streaming patent case against Google and YouTube for December 8, 2015. The release stated that the Company had requested the German court to order Google and YouTube to stop streaming video via using the current VP8 or H.264 video codecs and also to stop selling video-enabled devices like Nexus' Android(R) Phones and Chromecast(R) sticks. Max Sound has also requested information about any profits and that Google and YouTube are declared liable for damages based on patent infringement. The Company claims that Google and YouTube are using the technology protected by European Patent EP 2 026 277 Optimized Data Transmission. Max Sound is the inventor of the MAX-D HD Audio Standard, and is holder of the worldwide license and the exclusive right to sue to protect the above referenced patent.
- PositiveID Corp's stock soared 13.56% to close Thursday's session at USD 0.03. The company's shares oscillated between USD 0.02 and USD 0.03 in trade during the day. The stock recorded a trading volume of 10.93 million shares, which was much above its 30-day daily average volume of 2.78 million shares. Earlier on October 12, 2015, the Company announced a major development milestone with the production of a new and upgraded version of the Firefly Dx polymerase chain reaction ("PCR") breadboard prototype pathogen detection system ("prototype system"), which includes real-time optics for detecting pathogen in fewer than 20 minutes. According to the Company, real-time optics not only enables the measurement of fluorescence with every cycle of the PCR process, but is also used to understand the amount of pathogen present, and produces an "S-shaped" curve that can be identified. The Company noted that the S-shaped curve helps both responders and healthcare professionals understand the quality of the test being performed as well as to quantify the amount of pathogen present in the sample, which are crucial outcomes for determining the next steps following a positive result. William J. Caragol, Chairman and CEO of PositiveID commented, "This new prototype system is a big step forward in the development of a commercially available Firefly Dx unit as we move to capture a portion of the multi-billion dollar real-time PCR market. By incorporating real-time optics into our system, we can begin to measure the presence of a pathogen in real-time, which is an integral component of the Firefly Dx value proposition."
About Trader's Choice:
Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.
TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com
SOURCE: Trader's Choice